Target intelligence / Profile preview

Norovirus major capsid protein VP1 protruding domain (GI.1) (VP1 P domain (GI.1))

Target
VP1 P domain (GI.1)
Molecular classification
Viral structural protein, Capsid protein
01

Overview

The Norovirus VP1 P domain (GI.1) is the surface-exposed region of the major capsid protein VP1 of the Genogroup I, Genotype 1 norovirus, which is the prototypical Norwalk virus (Prasad et al., 1999, Science). This domain plays a pivotal role in viral infection by mediating attachment to host cells through interactions with Histo-Blood Group Antigens (HBGAs) (Tan & Jiang, 2005, J Virol). Structurally, the P domain is composed of P1 and P2 subdomains, where the P2 subdomain forms the most distal part of the viral capsid and contains the HBGA-binding interface (Donaldson et al., 2010, Immunol Rev). As the primary target for neutralizing antibodies, the P domain is the central component in the development of norovirus vaccines, such as Virus-Like Particles (VLPs) and P-particle candidates (Atmar et al., 2011, NEJM). Therapeutic strategies targeting this domain focus on small-molecule HBGA mimetics that competitively inhibit viral binding or monoclonal antibodies that block entry. Understanding the structural variability of the P domain is essential for addressing the challenges of strain diversity and antigenic drift in norovirus outbreaks.

Other names
Norwalk virus VP1 P domainProtruding domain of VP1GI.1 VP1 P domainNorovirus P domain
02

Mechanism of action

Inhibition of viral attachment to host histo-blood group antigens (HBGAs) and neutralization of viral entry through competitive binding or steric hindrance.

03

Biological functions

Host cell attachmentViral entryHisto-blood group antigen (HBGA) bindingCapsid assemblyAntigenic determinant
04

Disease associations

GastroenteritisInfection
05

Safety considerations

Antigenic drift and strain diversityShort-lived mucosal immunityPotential for antibody-dependent enhancement (theoretical)
06

Interacting drugs

TAK-214 (Vaccine candidate)

2 more in the full profile.

07

Biomarkers

Histo-blood group antigen (HBGA) secretor statusVP1-specific IgG titersVP1-specific IgA titers

Beyond the preview

Go deeper on Norovirus major capsid protein VP1 protruding domain (GI.1) (VP1 P domain (GI.1)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norovirus major capsid protein VP1 protruding domain (GI.1) (VP1 P domain (GI.1)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call